Tactile Systems Technology (NASDAQ:TCMD) is a medical device company focused on developing and commercializing innovative therapies for patients with lymphatic and vascular disorders. Headquartered in Minneapolis, Minnesota, the company’s flagship product is the Flexitouch® system, a home-based, pneumatic compression device designed to manage lymphedema, chronic venous insufficiency and other related conditions. Tactile Systems collaborates with physicians, therapists and payors to provide comprehensive treatment plans and patient support services aimed at improving clinical outcomes and quality of life.
Since its founding, the company has built a robust commercial infrastructure that includes a direct sales force, field-based clinical specialists and dedicated customer service teams. Tactile Systems delivers its products primarily in the United States and has established strategic partnerships and distribution agreements to expand its reach internationally. Through its network, the company offers training, reimbursement support and data analytics to help healthcare providers monitor patient adherence and measure the effectiveness of therapy.
In addition to the Flexitouch system, Tactile Systems markets a range of complementary products such as specialized garments, pump accessories and educational materials for both clinicians and patients. The company invests in ongoing research and development to enhance its existing platforms and explore new applications in vascular health, including wound management and diabetic foot care. Clinical studies and real-world evidence are integral to its strategy for driving adoption and demonstrating long-term benefits.
Tactile Systems Technology is led by a management team with deep expertise in medical devices, reimbursement and patient care. Under the leadership of Chief Executive Officer Charles Orcutt, the company emphasizes a patient-centric approach and continuous innovation. Its board and executive team leverage decades of combined experience to navigate regulatory processes, strengthen payer relationships and bring next-generation therapies to market.
